Phase distribution of chronic myeloid leukemia in Bangladesh

BMC Research Notes

M Anwar Hossain³  Subhagata Choudhury²  Md Sirazul Islam²  Siew Hua Gan¹  Md Ibrahim Khalil⁴  Tanvira Afroze Sultana²  Md Abdul Mottalib² 

[1] Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia;Laboratory Services Division, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders (BIRDEM), 122 Kazi Nazrul Islam Avenue, Shahbag, Dhaka, Bangladesh;Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh;Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh

关键词: Philadelphia chromosome;    RT-PCR;    Bangladesh;    Chronic myeloid leukemia;   

Others  :  1134304
DOI  :  10.1186/1756-0500-7-142

 received in 2013-09-18, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Here, we report the phase distribution of chronic myeloid leukemia (CML), defined based on the World Health Organization criteria, among 63 patients in Bangladesh. All patients were diagnosed based on complete blood count, bone marrow examination including bone marrow aspiration and reverse-transcriptase polymerase chain reaction (RT-PCR). Out of 63 patients, 42 were male and 21 were female. The mean age of the subjects was 37.4 years, with an age range of 17-60 years. The majority of patients (86%) were classified in the chronic phase (CP), 7 (11%) in the accelerated phase (AP) and two (3%) in blast crisis (BC). The most frequent patient age ranges were 21-30 years for CP, 41-50 years for AP and 41-50 years for BC.

Results

The Philadelphia chromosome was detected in 48 patients by RT-PCR. The mean total leukocyte counts, platelet counts, hemoglobin levels and marrow blast frequencies were 101 × 10⁹/L, 409 × 10⁹/L, 12.2 g/dl and 2.8% for CP; 121 × 10⁹/L, 418 × 10⁹/L, 8.7 g/dl and 15% for AP and 311 × 10⁹/L, 396 × 10⁹/L, 9.2 g/dl and 26% for BC, respectively.

Conclusion

This study concluded that most CML patients in Bangladesh are from a younger age group (31-40 years). In addition, males were more commonly affected, although females were afflicted with this disease at a younger age.

【 授权许可】

   
2014 Mottalib et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mughal TI, Goldman JM: Chronic myeloid leukemia. In Oxford Textbook of Oncology. 2nd edition. Edited by Souhami RL, Tannock I, Hohenberger P, Horiot JC. New York: Oxford University Press; 2002:2235.
• [2]Lee SJ: Chronic myelogenous leukaemia. Br J Haematol 2000, 111(4):993-1009.
• [3]Park K: Preventive and Social Medicine. 22nd edition. Jabalpur (India): M/s. Banarsidas bhanot publishers; 2002:547.
• [4]Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE: Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2009, 18(5):1501-1506.
• [5]McGuire TR, Kazakoff PW: Pharmacotherapy: A Pathophysiologic Approach. 4th edition. NY, USA: Elsevier; 1999.
• [6]Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, Rodella S, Tumino R, Crosignani P, Vindigni C: Alcohol consumption and risk of leukemia: a multicenter case–control study. Leuk Res 2007, 31(3):379-386.
• [7]Biggs J, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon A, Avalos B, Tutschka P, Kapoor N: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992, 80(5):1352-1357.
• [8]Hess G, Meyer RG, Schuch B, Bechthold K, El-Kholy I, Huber C: Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: 15 year follow up. Am J Hematol 2008, 83:178-184.
• [9]Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 2008, 111(3):1039-1043.
• [10]Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron WS: EER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2009.
• [11]Beane Freeman L, Blair A, Lubin J: Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. J Natl Cancer Inst 2009, 101:751-761.
• [12]Foon KA, Cassiato A: Dennis Chronic myelogenous leukemia. In Manual of Clinical Oncology. 5th edition. Edited by Casciato DA. Philadelphia: Lippincott Williams and Wilkins; 2004:491.
• [13]Chavan D, Ahmad F, Iyer P, Dalvi R, Kulkarni A, Mandava S, Das BR: Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population. Asian Pac J Cancer Prev 2006, 7(3):423.
• [14]Syed N, Usman M, Khaliq G, Adil S, Khurshid M: Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to Sokal score. J Coll Physicians Surg Pak 2006, 16(5):336.
• [15]Bhatti F, Ahmed S, Ali N: Clinical and hematological features of 335 patients of chronic myelogenous leukemia diagnosed at single centre in northern Pakistan. Clin Med Insights: Blood Disord 2012, 5:15-24.
• [16]Buchner-Daley L, Brady-West D: Chronic myeloid leukaemia at the University Hospital of the West Indies A 17-year review. West Indian Med J 2008, 57(5):493-496.
• [17]Ahmed R, Naqi N, Hussain I, Khattak BK, Nadeem M, Iqbal J: Presentating phases of chronic myeloid leukaemia. J Coll Physicians Surg Pak 2009, 19(8):469-472.
• [18]Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P: Management of chronic myeloid leukemia in France: a multi-centered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 2005, 14:545-553.
• [19]Cortes J, Kantarjian H, Giralt S, Talpaz M: Natural history and staging of chronic myelogenous leukaemia. Baillière’s Clin Haematol 1997, 10(2):277.
• [20]Aziz Z, Iqbal J, Akram M, Saeed S: Treatment of chronic myeloid leukemia in the imatinib era. Cancer 2007, 109(6):1138-1145.